MDCO Related Analyst Ratings
-
Jefferies Lifts Numbers on The Medicines Company (MDCO)
-
Guggenheim Starts The Medicines Company (MDCO) at Buy
-
Credit Suisse Starts The Medicines Company (MDCO) at Outperform
-
Jefferies Cuts Estimates But Lifts PT on The Medicines Co (MDCO) Post Q4
-
Needham & Company Boosts Alnylam (ALNY) PT to $28 on Medicines Co. Deal
-
Oppenheimer Comments on Medicines' (MDCO) Cangrelor Trial
-
ISI Group Starts The Medicines Company (MDCO) at Buy
-
SOLO-1 Data 'Solidifies' Medicines (MDCO) as M&A Target, Partner Candidate
-
JPMorgan Upgrades The Medicines Company (MDCO) to Overweight
-
Oppenheimer Starts The Medicines Company (MDCO) at Outperform
-
Jefferies Upgrades The Medicines Company (MDCO) to Buy, Attractive Reward/Risk
-
BofA/Merrill Lynch Starts The Medicines Company (MDCO) at Neutral
-
WallachBeth Capital Starts The Medicines Company (MDCO) at Buy
-
Auriga Reiterates a 'Buy' on The Medicines Company (MDCO); Continues to make progress on all front
-
Auriga Reiterates a 'Buy' on The Medicines Company (MDCO); Believe the Company is Well Positioned
-
Jefferies Starts The Medicines Company (MDCO) at Hold
-
Auriga Starts The Medicines Company (MDCO) at Buy
-
Citadel Securities Starts The Medicines Company (MDCO) at Add; Positive Resolution for Angiomax Patent Battle Expected
-
Argus Upgrades The Medicines Company (MDCO) to Buy
-
RBC Capital Downgrades Medicines Co. (MDCO) to Sector Perform
-
Wedbush Maintains a 'Neutral' on The Medicines Co (MDCO); Solicitor General Not to Appeal �At This Time�
-
Citi Maintains a 'Buy' on The Medicines Company (MDCO); Wins Patent Extension Ruling
-
Capstone Investments Initiates Coverage on The Medicines Company (MDCO) with a Buy
-
Citi 2Q10 SMID Biotech Earnings Preview: Adjusting AUXL & DNDN Models Ahead of Earnings; Top-Pick is BioMarin (BMRN)
-
RBC Capital Upgrades The Medicines Co. (MDCO) to Outperform
-
Wedbush Maintains an 'Underperform' on The Medicines Company (MDCO); Recent PTO Ruling Lowers Chance of Angiomax Patent Extension
-
Wedbush Morgan Downgrades The Medicines Company (MDCO) to Underperform
-
UBS Downgrades The Medicines Company (MDCO) to Neutral
-
Wedbush Morgan Upgrades Medicines Co. (MDCO) To Buy, Says Sell-Off Overdone
-
Citi Maintains a 'Buy' on The Medicines Company (MDCO), Adds to "Top Picks Live" List
-
Citi Maintains a 'Buy' on The Medicines Company (MDCO), Removes From Top Picks Live List
-
Citi Maintains a 'Buy' on The Medicines Company (MDCO), Adds Stock to Top Picks Live List
-
ARGUS Downgrades The Medicines Co. (MDCO) to Hold
-
Citi Top Biotech Ideas for 2009 (ALTH, MDCO)
-
Matrix USA Rating Changes 5/29
-
Citi Upgrades The Medicines Company (MDCO) to Buy
-
UBS upgrades Medicines Co. (MDCO) to Buy
-
RBC Capital upgradesMedicines Co. (MDCO) to Sector Perform
-
RBC Capital downgrades The Medicines (MDCO) to Underperform
-
Citigroup Initiates Coverage on Medicines Co. (MDCO)
-
UBS downgrades Medicines Co. (MDCO) to Reduce
-
UBS upgrades Medicines (MDCO) to Neutral
-
RBC Capital Upgraded Medicines Co (MDCO) to Sector Perform
-
Noble Financial Starts Medicines Co. (MDCO) at Strong Buy
-
Roth Capital upgrades MDCO to Strong Buy
-
First Albany Starts MDCO at Buy
-
Stanford Group Initiates MDCO
-
Roth Initiated MDCO
-
JP Morgan and CIBC downgrades MDCO
-
CIBC World Markets Upgrades MDCO
Back to MDCO Stock Lookup
